<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The role of <z:chebi fb="11" ids="18295">histamine</z:chebi> as a newly recognized sympathetic neurotransmitter has been presented previously, and its postsynaptic effects greatly depended on the activities of sympathetic nerves </plain></SENT>
<SENT sid="1" pm="."><plain>Cardiac sympathetic nerves become overactivated under <z:hpo ids='HP_0011009'>acute</z:hpo> myocardial ischemic conditions and release <z:chebi fb="65" ids="25512">neurotransmitters</z:chebi> in large amounts, inducing <z:hpo ids='HP_0004308'>ventricular arrhythmia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, it is proposed that cardiac sympathetic <z:chebi fb="11" ids="18295">histamine</z:chebi>, in addition to <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi>, may have a significant arrhythmogenic effect </plain></SENT>
<SENT sid="3" pm="."><plain>To test this hypothesis, we observed the release of cardiac sympathetic <z:chebi fb="11" ids="18295">histamine</z:chebi> and associated ventricular arrhythmogenesis that was induced by <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> in isolated mouse hearts </plain></SENT>
<SENT sid="4" pm="."><plain>Mast cell-deficient mice (MCDM) and histidine decarboxylase knockout (HDC(-/-)) mice were used to exclude the potential involvement of mast cells </plain></SENT>
<SENT sid="5" pm="."><plain>Electrical field stimulation and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion evoked chemical sympathectomy-sensitive <z:chebi fb="11" ids="18295">histamine</z:chebi> release from the hearts of both MCDM and <z:mp ids='MP_0002169'>wild-type</z:mp> (WT) mice but not from HDC(-/-) mice </plain></SENT>
<SENT sid="6" pm="."><plain>The release of <z:chebi fb="11" ids="18295">histamine</z:chebi> from the hearts of MCDM and WT mice was associated with the development of <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> and <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>The incidence and duration of induced <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> were found to decrease in the presence of the selective <z:chebi fb="11" ids="18295">histamine</z:chebi> H(2) receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="4975">famotidine</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>Additionally, the released <z:chebi fb="11" ids="18295">histamine</z:chebi> facilitated the arrhythmogenic effect of simultaneously released <z:chebi fb="1" ids="18357,33569">norepinephrine</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>We conclude that, under <z:hpo ids='HP_0011009'>acute</z:hpo> ischemic conditions, cardiac sympathetic <z:chebi fb="11" ids="18295">histamine</z:chebi> released by overactive sympathetic nerve terminals plays a certain arrhythmogenic role via H(2) receptors </plain></SENT>
<SENT sid="10" pm="."><plain>These findings provided novel insight into the pathophysiological roles of sympathetic <z:chebi fb="11" ids="18295">histamine</z:chebi>, which may be a new therapeutic target for <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-induced <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
</text></document>